- Trials with a EudraCT protocol (117)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
117 result(s) found for: Validation therapy.
Displaying page 1 of 6.
EudraCT Number: 2005-005474-77 | Sponsor Protocol Number: AGO/2005/004 | Start Date*: 2005-12-13 |
Sponsor Name:University Hospital Ghent | ||
Full Title: Validation of a pharmacologic profile of propofol | ||
Medical condition: Anesthesia | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2006-000908-17 | Sponsor Protocol Number: Siena Eye Cross Linking 2004 | Start Date*: 2007-01-11 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA SENESE | |||||||||||||
Full Title: Medical therapy of keratoconus with Riboflavin/Ultraviolet-A collagen Cross-Linking and investigation of the corneal stromal and Keratocytes modifications apoptosis and stromal repopulation with ... | |||||||||||||
Medical condition: Patients affected by keratoconus worsening | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-004228-37 | Sponsor Protocol Number: TransValid-KFO179/GRCSG-B | Start Date*: 2012-10-16 |
Sponsor Name:Universitätsmedizin Goettingen | ||
Full Title: Translational Validation Trial-B (add-on phase I/II study to the Clinical Research Unit (Klinische Forschergruppe) KFO179-2 | ||
Medical condition: Patients with advanced but resectable rectal cancer (clinically staged as rectal cancers of the UICC stages II, III or IV) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2010-021951-26 | Sponsor Protocol Number: UoL000621/R&D3963 | Start Date*: 2011-04-15 | |||||||||||
Sponsor Name:University of Liverpool [...] | |||||||||||||
Full Title: VIP: A prospective, phase II, double blinded, multicentre, randomised clinical trial comparing combination gemcitabine and vandetanib therapy with gemcitabine therapy alone in locally advanced or m... | |||||||||||||
Medical condition: Locally advanced or metastatic pancreatic cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-006102-23 | Sponsor Protocol Number: ImmuneRaRe_RF-2019-12369708 | Start Date*: 2021-10-13 | |||||||||||
Sponsor Name:OSPEDALE SAN RAFFAELE | |||||||||||||
Full Title: Study of a novel combination of immunovirologic and genetic parameters in early-treated HIV-1 patients undergone to antiretroviral therapy interruption (ATI) aimed at defining an algorithm predicti... | |||||||||||||
Medical condition: HIV-1 positive subjects treated with effective antiretroviral therapy during the acute phase of HIV-1 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-006381-29 | Sponsor Protocol Number: EXPRESSION | Start Date*: 2009-11-12 | ||||||||||||||||||||||||||
Sponsor Name:Universitätsmedizin Mainz | ||||||||||||||||||||||||||||
Full Title: Neoadjuvant, sequential chemotherapy with docetaxel followed by Fluorouracil, Epirubicin, and Cyclophosphamid every 3 weeks - genome wide expression analysis for identification of a predictive gene... | ||||||||||||||||||||||||||||
Medical condition: Eligible will be only females between 18 - 70 years of age, suffering from histologically confirmed primary breast cancer, nodal status positive or negative, phase cT2, cT3, or cT4 including inflam... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-000460-10 | Sponsor Protocol Number: EMR200104_10 | Start Date*: 2011-08-03 | ||||||||||||||||
Sponsor Name:Merck Serono SA | ||||||||||||||||||
Full Title: First year growth response associated genetic markers validation Phase IV open-label study in Growth Hormone Deficient and Turner Syndrome pre-pubertal children : the PREDICT Pharmacogenetics V... | ||||||||||||||||||
Medical condition: idiopathic growth hormone deficienty Turner Syndrome | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) ES (Completed) CZ (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-005011-17 | Sponsor Protocol Number: 7TNANO1 | Start Date*: 2015-02-24 |
Sponsor Name:Radboudumc | ||
Full Title: Nano MRI on 7 Tesla: A technical validation study in rectal and breast cancer | ||
Medical condition: Lymph node metastases in rectal cancer, breast cancer and cancer in general | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: View results |
EudraCT Number: 2017-004128-32 | Sponsor Protocol Number: KZM-PSMA-01 | Start Date*: 2017-12-01 |
Sponsor Name:Fakultní nemocnice Plzeň | ||
Full Title: Imaging of the prostate tumors using PET/CT and PET/MRI with the ligand of the prostatic specific membrane antigene 68Ga-PSMA-11 | ||
Medical condition: prostatic carcinoma higly suspected or its staging or restaging | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: CZ (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2015-001809-14 | Sponsor Protocol Number: E2015-PK-HD-PTAZ-MERO-CTAZ | Start Date*: 2015-06-24 | ||||||||||||||||
Sponsor Name:Hopital Erasme | ||||||||||||||||||
Full Title: Beta-Lactams (ceftazidime, piperacilline-tazobactam, meropenem) dosing scheme validation in septic hemodialysed patient | ||||||||||||||||||
Medical condition: sepsis in patient undergoing dialysis for renal insufficiency | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-001077-87 | Sponsor Protocol Number: IJB-RT-HNC-001 | Start Date*: 2019-08-08 | |||||||||||
Sponsor Name:Institut Jules Bordet | |||||||||||||
Full Title: Patient reported outcomes in term of swallowing and quality of life after prophylactic versus reactive percutaneous endoscopic gastrostomy tube placement in advanced head and neck cancer patients t... | |||||||||||||
Medical condition: advanced head and neck cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-005008-32 | Sponsor Protocol Number: ICORG13-17 | Start Date*: 2014-07-16 |
Sponsor Name:Cancer Trials Ireland | ||
Full Title: A phase II Study of the Efficacy and Safety of lenalidomide, subcutaneous bortezomib, and dexamethasone combination therapy for patients with newly diagnosed multiple myeloma | ||
Medical condition: Newly diagnosed multiple myeloma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2019-001545-41 | Sponsor Protocol Number: KO-MEN-001 | Start Date*: 2021-09-09 | |||||||||||
Sponsor Name:Kura Oncology, Inc. | |||||||||||||
Full Title: A Phase 1/2 First in Human Study of the Menin-MLL(KMT2A) Inhibitor KO-539 in Patients with Relapsed or Refractory Acute Myeloid Leukemia | |||||||||||||
Medical condition: Relapsed and/or refractory Acute Myeloid Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-006936-24 | Sponsor Protocol Number: FLOT65+ | Start Date*: 2007-07-17 |
Sponsor Name:Krankenhaus Nordwest GmbH | ||
Full Title: A multicenter, randomised phase II trial on the therapy of advanced gastric cancer or adenocarcinoma of the esophagogastric junction in patients older than 65 years with special regard on quality o... | ||
Medical condition: metastatic or locally advanced gastric cancer or adenocarcinoma of the esophagogastric junction | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2015-002337-22 | Sponsor Protocol Number: AEZS-130-052 | Start Date*: 2015-12-08 |
Sponsor Name:Aeterna Zentaris GmbH | ||
Full Title: Confirmatory validation of oral macimorelin as a Growth Hormone (GH) Stimulation Test (ST) for the diagnosis of Adult Growth Hormone Deficiency (AGHD) in comparison with the Insulin Tolerance Test ... | ||
Medical condition: Diagnosis of Adult Growth Hormone Deficiency (AGHD) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) AT (Completed) DE (Completed) PL (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-002512-49 | Sponsor Protocol Number: PRS-343-PCS_09_20 | Start Date*: 2022-06-13 |
Sponsor Name:Pieris Pharmaceuticals, Inc. | ||
Full Title: A Phase 2, Multi-Center, Open-Label Study of Cinrebafusp Alfa (PRS-343) in Combination with Ramucirumab and Paclitaxel in Patients with HER2-Positive Gastric or Gastroesophageal Junction (GEJ) Aden... | ||
Medical condition: HER2-Positive Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2019-000589-39 | Sponsor Protocol Number: ADP-0044-002 | Start Date*: 2020-02-13 | |||||||||||||||||||||
Sponsor Name:Adaptimmune LLC | |||||||||||||||||||||||
Full Title: A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR™ T cells in subjects with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma | |||||||||||||||||||||||
Medical condition: Advanced Synovial Sarcoma Myxoid/Round Cell Liposarcoma | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: FR (Trial now transitioned) GB (GB - no longer in EU/EEA) ES (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004250-17 | Sponsor Protocol Number: RG_18-205,BN3010 | Start Date*: 2019-10-11 | |||||||||||
Sponsor Name:University of Birmingham | |||||||||||||
Full Title: An International Prospective Trial on High-Risk Medulloblastoma in Patients Older than 3 Years | |||||||||||||
Medical condition: Histologically proven high-risk medulloblastoma, with any of the currently defined histological subtypes. High-risk disease is defined as patients with sonic hedgehog (SHH) subgroup or non-SHH/non-... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) AT (Trial now transitioned) DK (Trial now transitioned) IT (Trial now transitioned) NO (Trial now transitioned) NL (Trial now transitioned) BE (Trial now transitioned) SE (Trial now transitioned) CZ (Trial now transitioned) DE (Trial now transitioned) FI (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002643-23 | Sponsor Protocol Number: STH19966 | Start Date*: 2020-03-23 | ||||||||||||||||
Sponsor Name:Sheffield Teaching Hospitals NHS Foundation Trust | ||||||||||||||||||
Full Title: Validation of a novel composite of skin biomarkers as a primary outcome measure for evaluating the safety of treatments for atopic dermatitis: a randomized controlled trial (phase 2) comparing the ... | ||||||||||||||||||
Medical condition: atopic eczema (synonym atopic dermatitis) and the adverse treatment side effect epidermal atrophy | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-002564-24 | Sponsor Protocol Number: B490 | Start Date*: 2011-10-14 | |||||||||||
Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI | |||||||||||||
Full Title: Cetuximab and Cisplatin with or without Paclitaxel in recurrent/metastatic head and neck cancer | |||||||||||||
Medical condition: Recurrent/metastatic head and neck squamous cell carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
